Early Development & Drug Safety (EDDS)

PI-011 - ABSORPTION OF ELIGLUSTAT VIA THE BUCCAL CAVITY FOLLOWING ORAL ADMINISTRATION OF ELIGLUSTAT SOLUTION IN HEALTHY ADULT PARTICIPANTS.

PI-012 - CONCENTRATION-QT ANALYSIS FOR BAY 2927088 INDICATES NO CLINICALLY RELEVANT QTC INTERVAL PROLONGATION

PI-013 - CONSIDERATIONS ON HUMAN ADME STUDIES AND PROPOSED DECISION TREE TOWARDS TAILORED STUDY DESIGNS.

PI-014 - RESULTS OF A PHASE 1 CLINICAL TRIAL (GH001-HV-103) TO DETERMINE THE SAFETY AND TOLERABILITY OF MEBUFOTENIN (5-MEO-DMT), ADMINISTERED VIA INHALATION (GH001) IN HEALTHY SUBJECTS.

PII-011 - CHARACTERIZING QTC PROLONGATION RISK FROM CONCOMITANT MEDICATIONS IN PATIENTS WITH BREAST CANCER AMONG PHARMETRICS PLUS.

PII-012 - CONSIDERATIONS FOR PHASE 1 CLINICAL TRIALS IN ADULT PATIENTS

PII-013 - EVALUATING DRUG-DRUG INTERACTIONS WITH ACID-REDUCDING AGENTS: INSIGHTS FROM FDA GUIDANCE AND RECENT APPROVALS

PII-014 - SAFETY , TOLERABILITY, AND PHARMACOKINETICS OF SM17 IN HEALTHY VOLUNTEERS, A NOVEL IL-17 RECEPTOR B TARGETING ANTIBODY IN PHASE I DEVELOPMENT FOR THE TREATMENT OF ASTHMA

LB-003 - EXPLORING Δ-9-TETRAHYDROCANNABINOL (THC) INDUCED “FEELING HIGH” USING A PHYSIOLOGICALLY BASED PHARMACOKINETIC-PHARMACODYNAMIC MODEL